Sigilon Therapeutics launches with encapsulated cell therapy tech

Backed with $23.5 million from Flagship Pioneering, Sigilon Therapeutics launched today with a plan to leverage its biocompatible Afibromer technology with engineered cells to treat hematologic, enzyme deficiency and endocrine disorders.
Sigilon’s Afibromer platform represents a new class of implantable biomaterials that don’t trigger fibrosis, the company said. Encapsulated cell therapies have failed in the past in part because the body is designed to respond to and isolate foreign material. But capsules made from a biocompatible material, like Afibromers, could potentially help cell therapies survive the human immune system.
Get the full story at our sister site, Drug Delivery Business News.
The post Sigilon Therapeutics launches with encapsulated cell therapy tech appeared first on MassDevice.

Source: Mass Device - June 21, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Funding Roundup Implants Research & Development sigilontherapeutics Source Type: news